	US 11,987,812 B2
	Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same
Yoshikazu Yonemitsu, Fukuoka (JP); and Yui Harada, Fukuoka (JP)
Assigned to GAIA BioMedicine Inc., Fukuoka (JP); and Yoshikazu Yonemitsu, Fukuoka (JP)
Appl. No. 17/041,061
Filed by GAIA BioMedicine Inc., Fukuoka (JP); and Yoshikazu Yonemitsu, Fukuoka (JP)
PCT Filed Mar. 26, 2019, PCT No. PCT/JP2019/012744 § 371(c)(1), (2) Date Oct. 26, 2020, PCT Pub. No. WO2019/189115, PCT Pub. Date Oct. 3, 2019.
Claims priority of application No. 2018-059624 (JP), filed on Mar. 27, 2018.
Prior Publication US 2021/0095250 A1, Apr. 1, 2021
Int. Cl. C12N 5/0783 (2010.01); A61K 35/17 (2015.01); A61P 35/00 (2006.01); C12N 5/00 (2006.01)

CPC C12N 5/0646 (2013.01) [A61K 35/17 (2013.01); A61P 35/00 (2018.01); C12N 5/0081 (2013.01); C12N 2501/2302 (2013.01)]

12 Claims

1. A cell population comprising cells each being CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative.

8. A method for treating or preventing a solid tumor, comprising a step of administering the cell population according to claim 1 or the pharmaceutical composition according to claim 7 to a human.

10. A method for treating or preventing an infectious disease, comprising a step of administering the cell population according to claim 1 or the pharmaceutical composition according to claim 7 to a human.

11. A method for treating or preventing a cancer, comprising a step of administering the cell population according to claim 1 or the pharmaceutical composition according to claim 7 to a human.